Film Television Auditions – Lifestyle
Author:
Nanobiotix S.A.
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
April 20, 2026
Voting Rights and Shares Capital of the Company
April 7, 2026
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
April 1, 2026
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
March 30, 2026
NANOBIOTIX Statement Regarding Recent Media Speculation
March 25, 2026
Voting Rights and Shares Capital of the Company
March 12, 2026